Hair analysis as a new tool to monitor adherence to long‐term therapy to statins. Issue 5 (24th January 2023)

• Record Type: Journal Article
• Authors: Ballotari, Marco; Taus, Francesco; Gottardo, Rossella; Tagliaro, Franco; Bortolotti, Federica
• Other Names: Klampfl Christian W. guestEditor.
• Is Part Of: Electrophoresis. Volume 44:Issue 5/6(2023)
• Page Start: 521
• Page End: 528
• Publication Date: 2023-01-24
• Subjects: adherence to therapy -- hair analysis -- mass spectrometry -- statins; Electrophoresis -- Periodicals; Electrophoresis -- Periodicals; 541.372
• DOI: 10.1002/elps.202200210
• Languages: English
• ISSNs: 0173-0835

Abstract

Abstract: Statins are cholesterol‐lowering medications which are widely prescribed as first‐line treatment for hyperlipidemia, against high blood cholesterol aimed at reducing the risk of atherosclerotic diseases. Notwithstanding their undoubted efficacy, the needed long‐term treatment with these drugs is characterized by a high percentage of dropout. Consequently, an effective tool to verify the patients' compliance to statin therapy is needed. In this context, the analysis for drugs and drug metabolites in the hair may represent an almost ideal tool because, according to a sound body of forensic toxicological literature, concentrations in the hair matrix reflect the chronic intake of drugs and pharmaceuticals. In this light, in the present study, a novel, specific and sensitive ultra‐performance liquid chromatography–tandem mass spectrometry method has been developed to determine six statins and their metabolites (namely atorvastatin, ( p )α‐OH‐atorvastatin‐lactone, ( o )α‐OH‐atorvastatin‐lactone, rosuvastatin, N ‐desmethyl rosuvastatin and pravastatin) in human hair. After optimization, the method was successfully validated in terms of selectivity, linearity, sensitivity, precision, accuracy, stability and matrix effect. Moreover, the practical applicability of this method for verifying adherence to statin therapy was assessed by testing samples of hair collected from subjects under long‐term therapy with statins.